Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Amphastar Pharmaceuticals IncAMPH16.673.753.799.1425.57%8.23%40.93$46.22$191.927,473$46.32

Detail of Amphastar Pharmaceuticals Inc

 
CEO
Dr. Yongfeng Zhang Ph.D.
Employees
1761
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Market cap
$2B

Company details

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$601.31M
Cost of goods (CoG)
-$275.16M
Gross profit (GP)
$326.15M
Operating expense (OE)
-$145.31M
Research and development (R&D)
-$70.56M
General and administrative (G&A)
-$74.75M
Operating income (OI)
$180.84M
Other income expense (OIE)
-$9.56M
Pretax income (PI)
$171.27M
Tax (TAX)
-$34.45M
Net income (NI)
$135.29M
Amphastar Pharmaceuticals Inc
AMPH • XNGS • US
$46.32
-1.64 (-3.42%)
Stock vs Industry average
  • Industry average

Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
$2.78
Margin profit
23.36%
52 week low
$36.990002
52 week high
$63.450001
50-day simple moving average
$46.96
200-day simple moving average
$46.22
Percent held by insiders
22.33%
Percent held by institutions
72.20%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
AMPH -4.42%
eps change
AMPH +215.62%